Taxonomy Code 1835X0200X(1835x0200x)
Oncology Pharmacist. Providers: 31
Oncology Pharmacist Providers
| NPI | Name | Type | Address |
|---|---|---|---|
|
PHARMD Jane Lee |
Individual |
55 Park St New Haven, CT |
|
|
PHARMD Danielle Brown |
Individual |
55 Park St New Haven, CT |
|
|
PHARMD Molly Laura Schiffer |
Individual |
55 Park St New Haven, CT |
|
|
DR. PHARM D Usama Abdelghany |
Individual |
20 York St New Haven, CT |
|
|
DR. PHARM.D. Annette Podgorski Hood |
Individual |
55 Park St New Haven, CT |
|
|
PHARMD Megan P Pereira |
Individual |
55 Park St New Haven, CT |
|
|
Leonora Novak |
Individual |
55 Park St New Haven, CT |
|
|
DR. PHARM.D. Hiba Ahmad |
Individual |
55 Park St New Haven, CT |
|
|
Barbara Cmuchowski |
Individual |
35 Park St New Haven, CT |
|
|
MR. R.PH., BCOP Thomas Michael Ferencz |
Individual |
55 Park St New Haven, CT |
|
|
PHARMD Alexandra Igoumenos |
Individual |
55 Park St New Haven, CT |
|
|
Andrew Kowalski |
Individual |
55 Park St New Haven, CT |
|
|
Sergio F Toni JR. |
Individual |
20 York St New Haven, CT |
|
|
DR. PHARMD Mark Wysocki |
Individual |
55 Park St New Haven, CT |
|
|
Brenda Yik |
Individual |
55 Park St New Haven, CT |
|
|
PHARMD Sara Mohamed Jaszczur |
Individual |
55 Park St New Haven, CT |
|
|
Jennifer Chen Zhao |
Individual |
55 Park St New Haven, CT |
|
|
DR. PHARMD Trinh Pham |
Individual |
55 Park St New Haven, CT |
|
|
PHARMD Laura Tuttle |
Individual |
55 Park St New Haven, CT |
|
|
Ying Long |
Individual |
55 Park St New Haven, CT |
How to obtain, renew, or terminate an NPI
Every health care provider, whether it’s a hospital, pharmacy, or individual specialist, must obtain their own NPI number. This identification number is unique and is assigned upon application. In tod...
| Taxonomy Code | 1835X0200X |
| Specialization | Oncology |
| Display Name | Oncology Pharmacist |
| Taxonomy Group | Pharmacy Service Providers |
| Taxonomy Classification | Pharmacist |
| Definition | A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases. |
| Effective Date | September 30, 2009 |